Reye Syndrome
Clinical Snapshot
Reye syndrome is a rare, acute, non-inflammatory encephalopathy accompanied by fatty degeneration of the liver, affecting mainly children and teenagers, typically during or shortly after a viral illness such as chickenpox (varicella) or influenza.[1] Aspirin (acetylsalicylic acid, ASA) use during that viral illness has been strongly linked to its development, and current Canadian regulation requires every over-the-counter ASA-containing product to carry an explicit warning against use in anyone under 18 years of age with chicken pox, cold, or flu symptoms.[1][2] Untreated or unrecognized, Reye syndrome is genuinely dangerous: Health Canada's own figures put case fatality at 20-30%, with permanent brain damage among survivors.[1]
This chapter's central fact: Reye syndrome is now overwhelmingly a story of successful prevention, not acute treatment. US national surveillance recorded roughly 555 cases in 1979-1980 alone and an average of around 100 cases per year through the mid-1980s; following the 1982 U.S. Surgeon General's advisory and 1986 FDA-mandated warning labels, reported cases fell to an average of 36 per year by 1987-1993 and to fewer than 2 cases per year nationally since 1994.[3][4] The United Kingdom saw an almost identical pattern — 79 cases in 1983/84 falling to 19 by 1988/89 after its own 1986 public warning.[5] For a practising pharmacist today, this means Reye syndrome is a condition you will very rarely see in crisis but should counsel against routinely and confidently — see Non-Pharmacologic Treatment for the specific, practical counselling framework this chapter treats as its centerpiece.
Because the disease itself is now so rare, a portion of children historically diagnosed with "Reye syndrome" — particularly those under 2 years of age, those with recurrent episodes, or those without a clear preceding viral illness or documented salicylate exposure — are, on more sophisticated modern metabolic testing, ultimately found to have an underlying inborn error of metabolism instead (see Assessment & Diagnosis and Special Populations).[5][4]
Recognize the Condition
The classic biphasic pattern
Reye syndrome classically follows a biphasic course: a child has an ordinary viral illness — an upper respiratory infection or influenza-like illness, chickenpox, or a gastroenteritis-type illness — and appears to be recovering, then, typically 3-7 days after the viral illness began (StatPearls describes a wider possible window of 12 hours to 3 weeks, most commonly 3-6 days), develops sudden, persistent, forceful vomiting, often without diarrhea, that is frequently the first thing a caregiver notices.[6][4] Within hours, this is followed by rapidly progressive changes in mental status and behaviour.[6][4]
What families and frontline staff actually observe
- Persistent, repeated vomiting in a child or teenager who seemed to be getting better.[6]
- Unusual sleepiness or lack of energy, or the opposite — irritability, agitation, or aggressive/combative behaviour that is out of character.[6]
- Confusion, disorientation, or slurred speech.[6]
- Progressing, if unrecognized, to seizures and coma.[6]
- No jaundice — this is a genuinely important negative finding, not an oversight; despite significant hepatic involvement, the skin and sclerae typically do not turn yellow, because bilirubin handling itself is preserved even though transaminases and ammonia are markedly elevated (see Assessment & Diagnosis).[7]
- Hepatomegaly is found on examination in roughly 40% of cases, typically non-tender.[7]
- Focal neurologic findings (weakness on one side, cranial nerve deficits) are typically absent — their presence should prompt reconsideration of the diagnosis (see Assessment & Diagnosis).[7]
The five-stage clinical scale
Once encephalopathy is recognized, clinical staging both communicates severity and drives the intensity of supportive care (see Choose Initial Treatment).
| Stage | Clinical features |
|---|---|
| Stage 1 | Vomiting, lethargy, confusion |
| Stage 2 | Stupor, disorientation, hyperreflexia, hyperventilation |
| Stage 3 | Obtunded or comatose, with decorticate rigidity |
| Stage 4 | Fixed and dilated pupils, deep coma, decerebrate rigidity |
| Stage 5 | Seizures, flaccid paralysis, loss of deep tendon reflexes, respiratory arrest |
[4] Reported mortality tracks this staging closely — under 2% in Stage 1, rising to over 80% in Stages 4-5 — which is the clearest possible illustration of why early recognition, at the vomiting-plus-mental-status-change stage rather than after progression to stupor or coma, is the single highest-value clinical action in this chapter.[7]
Risk Factors
- Age. Reye syndrome affects mainly children and teenagers; StatPearls reports a peak incidence age of 5-14 years, though cases occur in infants and young children as well — a group in which an underlying inborn error of metabolism is a more likely explanation for a similar presentation (see Assessment & Diagnosis and Special Populations).[1][4]
- A preceding viral illness is present in the great majority of cases. In US surveillance data, influenza A or B preceded roughly 73% of cases, varicella (chickenpox) preceded roughly 21%, and a gastroenteritis-type illness preceded roughly 14%; less common associations include coxsackievirus, Epstein-Barr virus, cytomegalovirus, adenovirus, and certain bacterial infections (Mycoplasma, Bordetella pertussis, Shigella, Chlamydia).[4]
- Salicylate (aspirin) exposure during that viral illness is the dominant, causally implicated risk factor — more than 80% of children diagnosed with Reye syndrome had taken aspirin in the preceding three weeks.[4] This is the single fact this chapter's counselling centerpiece exists to act on; see Non-Pharmacologic Treatment.
- Seasonal clustering broadly December through April, tracking influenza and varicella season.[4]
- A minority of cases occur without any documented salicylate exposure. In the current, post-warning era, an apparent Reye-syndrome-like illness without a clear salicylate history — especially in a young child, or with recurrent episodes — should raise suspicion for an underlying inborn error of metabolism rather than being accepted as idiopathic Reye syndrome (see Assessment & Diagnosis).[5][4]
On risk communication: the absolute risk of Reye syndrome in any individual aspirin-exposed child during a viral illness is low — well under 0.1% of exposed children develop it.[4] That low absolute risk is not, on its own, a reason to permit the exposure: Reye syndrome is severe when it does occur (20-30% case fatality, permanent brain damage among survivors), a fully effective, inexpensive, age-appropriate alternative exists (acetaminophen or ibuprofen), and Canadian regulation reflects exactly this reasoning by prohibiting ASA products from being marketed or advertised for use in children or teenagers at all.[1][2] Pharmacists can counsel with genuine confidence: there is no scenario in routine pediatric fever/pain management where salicylate exposure is worth the risk when a safe substitute is available.
Red Flags & Refer
- Persistent, repeated, forceful vomiting following apparent recovery from a viral illness, together with any change in mental status or behaviour (unusual sleepiness, confusion, agitation, aggression, or slurred speech) — this combination is the presentation to escalate immediately and emergently; do not manage it as routine post-viral vomiting or "wait and see" overnight.[6][1]
- Any seizure, loss of consciousness, or posturing occurring in this context is a medical emergency — call emergency medical services or go directly to an emergency department.[6]
- Rapid progression can occur within hours from the first vomiting episode to significant encephalopathy; the window to intervene safely at home is short, and the correct instruction to caregivers is to seek emergency care at the first sign of altered behaviour or mental status, not after it has clearly worsened.[4]
- Any known aspirin or salicylate-containing-product exposure during the preceding viral illness should be explicitly and proactively disclosed to the treating team by the caregiver or pharmacist — it meaningfully raises the index of suspicion specifically for Reye syndrome and should not be left for the emergency team to elicit unprompted.
- Signs of elevated intracranial pressure — abnormal posturing (decorticate or decerebrate), fixed/dilated pupils, or irregular respirations — indicate advanced disease requiring immediate PICU-level care (see Choose Initial Treatment).[4]
Assessment & Diagnosis
Diagnostic criteria
Reye syndrome is diagnosed clinically, supported by a characteristic laboratory pattern, and is ultimately a diagnosis of exclusion. The commonly used diagnostic criteria require all three of the following: (1) an acute, non-inflammatory encephalopathy — altered consciousness, with cerebrospinal fluid, if sampled, showing 8 leukocytes/mm³ or fewer; (2) hepatopathy, confirmed either by liver biopsy showing the characteristic changes or by at least a threefold elevation in AST/ALT or ammonia; and (3) no better alternative explanation for the encephalopathy or hepatic abnormality.[4]
The central laboratory pearl: elevated transaminases and ammonia with a normal bilirubin
This is the single most important laboratory teaching point in this chapter. Reye syndrome produces markedly elevated AST and ALT (typically more than three times the upper limit of normal), an elevated blood ammonia level, and a prolonged prothrombin time — together with a normal bilirubin.[4][7] This pattern — real, significant hepatic dysfunction without jaundice or hyperbilirubinemia — genuinely distinguishes Reye syndrome from viral hepatitis and most other causes of acute hepatic failure, where hyperbilirubinemia is expected, and it explains why the classic presentation described in Recognize the Condition specifically lacks jaundice despite hepatomegaly and abnormal liver enzymes.[7] Ammonia is often the earliest and most sensitive abnormality, typically rising within 1-2 days of the encephalopathy's onset, and the degree of elevation correlates with clinical severity and prognosis.[4]
Other supporting laboratory and CSF findings
- Hypoglycemia — a common and directly treatable finding, especially in younger children (see Choose Initial Treatment).[4]
- Prolonged prothrombin time and other coagulopathy from impaired hepatic synthetic function.[4]
- Metabolic acidosis and electrolyte disturbance are common, reflecting both the illness itself and the effects of persistent vomiting.[4]
- Cerebrospinal fluid, when sampled to exclude meningitis/encephalitis, characteristically shows 8 leukocytes/mm³ or fewer and normal protein, with increased opening pressure reflecting cerebral edema rather than infection.[4]
- Liver biopsy provides the definitive diagnosis when performed — diffuse microvesicular fatty infiltration of hepatocytes, notably without significant necrosis or inflammatory infiltrate, again contrasting with the necroinflammatory picture of viral hepatitis. It is now rarely performed given the syndrome's rarity, its invasiveness, and improved non-invasive recognition, but remains particularly useful in sporadic or atypical cases.[4]
- Neuroimaging (CT or MRI) may show diffuse cerebral edema; it does not confirm the diagnosis but is used to exclude a mass lesion, hemorrhage, or stroke and to help guide intracranial pressure management.
The differential diagnosis — inborn errors of metabolism are genuinely important, not a footnote
| Condition | Key distinguishing features |
|---|---|
| Reye syndrome | Biphasic course after a viral illness (classically influenza or varicella), documented or probable salicylate exposure, elevated transaminases/ammonia with normal bilirubin, CSF ≤8 WBC/mm³, typically age 5-14 |
| Fatty acid oxidation disorders (e.g., medium-chain acyl-CoA dehydrogenase [MCAD] deficiency) | Presents with a Reye-like illness, often precipitated by fasting/intercurrent illness rather than requiring salicylate exposure; more likely in infants and young children, recurrent episodes, or a family history of unexplained infant death |
| Urea cycle disorders (e.g., ornithine transcarbamylase [OTC] deficiency) | Hyperammonemia and encephalopathy without a clear preceding viral illness or salicylate exposure; recurrent episodes; X-linked OTC deficiency classically affects males but can present in female carriers |
| Organic acidemias | Metabolic acidosis often more pronounced than typical Reye syndrome; recurrent episodes; abnormal newborn screen may already be on record |
| Salicylate toxicity itself | Tinnitus, hyperventilation/respiratory alkalosis with metabolic acidosis, elevated salicylate level; a distinct entity from Reye syndrome, though both involve aspirin |
| Valproate-associated hepatotoxicity ("Reye-like syndrome") | Occurs in a child on valproic acid, especially under 2 years of age or with an undiagnosed underlying mitochondrial disorder, rather than following aspirin exposure |
| Viral encephalitis / bacterial meningitis | CSF pleocytosis (more than 8 WBC/mm³) and/or meningismus, unlike the characteristically bland CSF of Reye syndrome |
| Sepsis with hepatic dysfunction | Fever, hemodynamic instability, positive cultures; hepatic picture usually accompanied by other organ dysfunction |
[4][7] Any child under 2 years of age, any child with a recurrent "Reye-like" episode, and any presentation without a clear preceding viral illness or documented salicylate exposure should prompt an urgent metabolic work-up (plasma amino acids, urine organic acids, acylcarnitine profile, and urine orotic acid if a urea cycle disorder is suspected) in parallel with — not instead of — standard supportive management, together with metabolic genetics involvement.[4] This is not a theoretical concern: in a UK national surveillance review of 418 cases diagnosed as Reye syndrome, 89 diagnoses were later revised on more sophisticated testing, and 36% of those revisions were to an inborn error of metabolism — a striking, concrete reminder that "presumed Reye syndrome" in the wrong clinical context deserves a genuine metabolic work-up, not just a mention in the differential.[5]
Treatment Targets
- Recognize the biphasic pattern — vomiting following apparent recovery from a viral illness, then altered mental status — early enough to escalate before significant neurologic injury occurs.
- Correct and maintain euglycemia throughout the acute illness.
- Prevent and treat cerebral edema and manage elevated intracranial pressure aggressively when present, matched to clinical stage.
- Correct coagulopathy and other metabolic derangements (acidosis, electrolyte disturbance).
- Actively exclude — in parallel, not sequentially — an underlying inborn error of metabolism or another alternative diagnosis, particularly in a young child or a recurrent presentation.
- Provide meticulous, stage-matched supportive/ICU care, since no specific antidote or disease-modifying drug exists.
- Support full neurologic recovery, which is achievable for most patients when recognized and treated promptly.
- Prevent the next case. Given how rare and how severe this condition is, and how directly modifiable the salicylate risk factor is, primary-prevention counselling is, in practical terms, this chapter's single most impactful pharmacist-level intervention — see Non-Pharmacologic Treatment.
Choose Initial Treatment
No specific antidote exists — management is stage-matched, ICU-level supportive care
There is no disease-modifying drug therapy for Reye syndrome; corticosteroids have been tried historically without demonstrated benefit and are not recommended.[4] Management is entirely supportive, organized around the clinical stage in Recognize the Condition.
Stage 1-2 (lethargy/confusion, hyperreflexia, hyperventilation, no posturing) close monitoring, strongly consider PICU admission given how quickly progression can occur, and reassess neurologic status frequently.[4]
Stage 3-5 (obtunded/comatose, posturing, fixed/dilated pupils, seizures) PICU/ICU admission is mandatory: secure the airway (intubation is frequently required), establish intracranial pressure monitoring, and proceed directly to the cerebral-edema protocol below.[4]
Maintain euglycemia with dextrose-containing IV fluids, targeting a glucose range of roughly 100-120 mg/dL; check glucose frequently, since hypoglycemia is common — particularly in younger children — and independently worsens neurologic outcome if uncorrected.[4]
For Stage 3 and higher: elevate the head of the bed to 30° with the head midline, maintain normothermia (treat fever aggressively), provide adequate sedation/analgesia to blunt intracranial-pressure spikes, treat seizures promptly, and use osmotic therapy — mannitol or hypertonic saline — for acutely elevated intracranial pressure.[4] Avoid unnecessary agitation, suctioning without adequate pre-oxygenation/sedation, and other maneuvers known to provoke ICP spikes. Continuous ICP monitoring is appropriate in higher-stage disease to guide this therapy in real time.[4]
Give vitamin K for the prolonged prothrombin time expected with hepatic synthetic dysfunction, and add fresh frozen plasma or cryoprecipitate for active bleeding or significant coagulopathy, particularly before any invasive procedure (e.g., ICP monitor placement).[4]
For severe hyperammonemia, ammonia-scavenging therapy (sodium benzoate/sodium phenylacetate) can be considered, and hemodialysis or continuous renal replacement therapy is an option for markedly elevated levels (StatPearls cites a threshold above roughly 500 mcg/dL) — both are specialist-directed, typically involving critical care and metabolic/toxicology consultation.[4]
Correct significant metabolic acidosis cautiously with sodium bicarbonate as needed, guided by serial blood gas monitoring.[4]
Do not give any aspirin- or salicylate-containing product at any point in this presentation or its recovery — this should be self-evident, but confirm no salicylate-containing product (including bismuth subsalicylate, given for the antecedent GI symptoms) remains in the treatment plan; use acetaminophen, dosed cautiously given the hepatic involvement, if antipyresis is separately needed.[1][6]
Non-Pharmacologic Treatment
Supportive care during the acute episode
- General ICU-level supportive nursing care: positioning, temperature control, seizure precautions, and meticulous neurologic-status monitoring matched to clinical stage.
- Hold enteral feeds during significant encephalopathy given aspiration risk and likely ileus; once stabilized, resume nutrition with an initial, short-term caution around protein and fat intake, transitioning back to normal intake as hepatic function recovers — this caution should be short-term only, not a lasting dietary restriction, unless an underlying inborn error of metabolism specifically requiring long-term dietary management is ultimately confirmed (see Assessment & Diagnosis).
- Assess swallowing safety before resuming oral intake in any child recovering from Stage 3 or higher encephalopathy.
The counselling centerpiece: aspirin and salicylate avoidance — the pharmacist's highest-yield intervention for this condition
Because Reye syndrome is now so rare and its trigger so specific, primary-prevention counselling is, in practical terms, the intervention most pharmacists will actually deliver for this condition — far more often than acute management. Health Canada regulation is explicit and specific: every over-the-counter product containing acetylsalicylic acid must carry the warning "Do not give to children and teenagers less than 18 years of age who have chicken pox, cold or flu symptoms before a physician or pharmacist is consulted about Reye's Syndrome, a rare serious illness reported to be associated with acetylsalicylic acid," and ASA products may not be advertised for use by children or teenagers at all.[2][1] This applies to anyone under 18 years of age with a current fever, cold, flu-like illness, chickenpox, or upset-stomach/nausea symptoms — not only a confirmed influenza or varicella diagnosis.[1][6]
Products caregivers genuinely do not recognize as salicylate-containing
- Bismuth subsalicylate (the active ingredient in products such as Pepto-Bismol-type stomach remedies) is itself a salicylate and is specifically named by Canadian public health sources as one to avoid in this age group — and it is a genuinely dangerous blind spot precisely because caregivers reach for a "stomach medicine" during the exact viral GI illness that is itself a recognized Reye syndrome trigger, without connecting it to "aspirin" at all.[6][4]
- Combination analgesic products containing ASA alongside caffeine, codeine, or a buffering agent, which may be borrowed "just this once" from an adult household member's supply without the caregiver recognizing the ASA component.
- Effervescent multi-symptom or "upset stomach and pain" products containing ASA, which read to many caregivers as an antacid rather than an aspirin product.
- Topical salicylate-containing rubs and liniments (methyl salicylate, "oil of wintergreen") — a different exposure route and toxicity concern from oral ASA, but still worth asking about, especially with heavy or occlusive use in a child.
- Herbal or "natural" products containing willow bark (salicin, the natural precursor of acetylsalicylic acid), which a caregiver actively trying to avoid "aspirin" may reach for without recognizing the underlying chemistry is the same.
The practical counselling framework
- Teach caregivers to read the active-ingredient panel of every OTC product before giving it to anyone under 18, specifically scanning for "ASA," "acetylsalicylic acid," "aspirin," "salicylate," or "salicylic acid" — not to rely on the product's marketed use category ("stomach reliever," "cold and flu") or brand familiarity alone.
- Ask, don't assume. A caregiver who would correctly answer "no" to a direct "did you give aspirin?" question may still have given a salicylate-containing product without recognizing it as one — ask specifically what products (including "stomach," "cold," or any borrowed adult) medication the child has already received.
- Reinforce the safe alternatives confidently: acetaminophen, or ibuprofen (avoiding ibuprofen under 6 months of age without first consulting a healthcare provider), are effective, appropriate, and carry no Reye syndrome signal — there is no reason to accept salicylate exposure in this age group when a fully adequate substitute exists.[6]
- Own the point-of-sale role. A pharmacist recommending or dispensing any OTC product for a feverish, "flu-like," or chickenpox-affected child or teen is genuinely the last checkpoint before an inadvertent salicylate exposure leaves the pharmacy — this single check is one of the most concrete, high-yield preventive actions available in this entire chapter.
- Know the one deliberate exception so that counselling stays accurate rather than absolute: children with Kawasaki disease are, by design, treated with acute- and maintenance-phase aspirin as a guideline-endorsed exception to this general avoidance — see this platform's Kawasaki Disease chapter for that specific protocol, including the temporary antiplatelet switch (to clopidogrel or dipyridamole) if such a child develops varicella or influenza, and the recommendation that these children receive annual influenza vaccination. Do not deliver a blanket "never give your child aspirin" message that contradicts a physician-directed exception a family may already be correctly following.
Ordinary post-viral vomiting versus the red-flag pattern
Most vomiting during a routine childhood viral illness is not Reye syndrome. Routine caregiver guidance — small, frequent sips of fluid, oral rehydration solution if needed, and gradual reintroduction of food — remains appropriate for ordinary viral-illness vomiting. What distinguishes the pattern in this chapter is the combination of persistent, forceful vomiting with any accompanying change in mental status or behaviour, particularly following apparent recovery from the initial illness — see Red Flags & Refer.
Special Populations
Infants and children under 2 years
An inborn error of metabolism — particularly a fatty acid oxidation disorder (e.g., MCAD deficiency) or a urea cycle disorder (e.g., OTC deficiency) — is a substantially more likely explanation for a Reye-like presentation at this age than true Reye syndrome. Pursue urgent metabolic work-up (plasma amino acids, urine organic acids, acylcarnitine profile, urine orotic acid) in parallel with standard supportive care rather than sequentially, and involve metabolic genetics early (see Assessment & Diagnosis).[4][5]
Recurrent "Reye-like" episodes, or no documented salicylate exposure
Treat as presumptive inborn error of metabolism until proven otherwise, and pursue the same urgent metabolic work-up. A family history of unexplained infant or early childhood death is a specific additional prompt to pursue this work-up aggressively.[4]
Varicella-exposed children
Chickenpox is one of the two classic viral triggers for Reye syndrome and remains a specific, named prompt for aspirin-avoidance counselling in Canadian public health messaging.[1][2] Reinforce this counselling explicitly at the point a chickenpox diagnosis is made or suspected, and during any local varicella activity, independent of whether the child has been varicella-vaccinated.
Influenza season
Reinforce salicylate-avoidance counselling proactively during flu season — at influenza vaccination visits, and whenever recommending or dispensing any OTC product for a feverish child or teenager.
Children on chronic salicylate therapy for another indication
A small number of children remain on long-term aspirin therapy for a specific, physician-directed indication — the clearest example on this platform is Kawasaki disease, where acute- and maintenance-phase aspirin is a deliberate, guideline-endorsed exception to routine pediatric salicylate avoidance (see the Kawasaki Disease chapter). These children need a temporary switch to an alternative antiplatelet agent (clopidogrel or dipyridamole) if they develop varicella or influenza while on aspirin, and are specifically recommended to receive annual influenza vaccination to reduce exposure to one of the two classic triggers. Counsel these families with the specific nuance intact rather than a blanket "never give aspirin" message.
Households with an adult on chronic low-dose ASA
A grandparent or other household member on cardioprotective low-dose aspirin represents a real, practical inadvertent-exposure risk for a child in the home — counsel on secure, separate storage, and specifically ask about this when taking a medication history for any ill child.
Monitoring & Follow-Up
- Track neurologic status and clinical stage trend at frequent, defined intervals; where ICP monitoring is in place, use it to guide osmotic therapy and sedation in real time rather than relying on intermittent clinical exam alone.
- Trend glucose, ammonia, transaminases, bilirubin, and coagulation studies serially — ammonia trajectory in particular correlates with clinical severity and is useful prognostically, distinct from its diagnostic role at presentation.[4]
- Arrange long-term neurodevelopmental follow-up for survivors, particularly those who experienced seizures or decerebrate/decorticate posturing during the acute illness, since this group carries a meaningfully higher risk of residual neurologic deficit.[7]
- Where a metabolic work-up was pursued, ensure results are actively followed up and communicated — an identified inborn error of metabolism carries genetic-counselling and family-planning implications well beyond the index episode.
- Document a clear, durable flag in the patient's record for any confirmed Reye syndrome episode: salicylate/ASA avoidance should be considered indefinite going forward, not limited to the acute recovery window, and every future caregiver (including school and daycare staff) should know it.
- At every subsequent pharmacy contact with the family — for this child or any sibling — reinforce the aspirin/salicylate-avoidance counselling framework in Non-Pharmacologic Treatment; household risk factors and habits are shared across siblings.
Common Errors to Avoid
- Treating persistent vomiting plus a mental status or behaviour change following a viral illness as routine dehydration or "just the flu" without specifically asking what OTC products the child received during the preceding illness.
- Waiting overnight, or for symptoms to "prove themselves," before seeking emergency care — progression can occur within hours.[4]
- Relying on jaundice or an elevated bilirubin to confirm hepatic involvement — a normal bilirubin alongside elevated transaminases and ammonia is the expected, classic pattern, not a reason to lower suspicion for Reye syndrome.[7][4]
- Accepting an apparent Reye syndrome diagnosis at face value in a child under 2 years of age, with recurrent episodes, or without a clear preceding viral illness or documented salicylate exposure, instead of pursuing an urgent metabolic work-up — historical data show a genuinely substantial share of such cases are ultimately inborn errors of metabolism.[5]
- Asking only "did you give aspirin?" instead of asking specifically about all products given, including bismuth subsalicylate ("stomach medicine"), combination analgesics, and any borrowed adult medication — a caregiver can correctly and honestly say "no" to the direct question while having given a salicylate-containing product without recognizing it.[6]
- Delivering a blanket "never give your child aspirin" message without the Kawasaki disease exception nuance for a family already correctly following a physician-directed chronic-ASA regimen — see Special Populations and the Kawasaki Disease chapter.
- Continuing protein/fat dietary restriction beyond the acute recovery phase without a confirmed inborn error of metabolism specifically requiring it — the correct approach is short-term caution during active encephalopathy, not a lasting dietary restriction.
- Recommending or dispensing any ASA- or salicylate-containing product (including bismuth subsalicylate) for anyone under 18 with a current fever, cold/flu-type illness, or chickenpox without first checking the active-ingredient panel — brand recognition and marketed use category are not reliable enough on their own.[2]
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Salicylates — Avoid in Anyone Under 18 During a Current Viral Illness
Both entries below are salicylates, strongly linked to Reye syndrome. Canadian regulation requires an explicit Reye syndrome warning on every OTC ASA-containing product and prohibits marketing ASA products for use by children or teenagers.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Acetylsalicylic acid (ASA / aspirin) | Use in this context: Contraindicated — see Non-Pharmacologic Treatment for the counselling framework | Reye syndrome (encephalopathy with hepatic dysfunction) when used during a viral illness in this age group; GI upset and bleeding risk at any age | Additive bleeding risk with other antiplatelets/anticoagulants | Do not use for fever, pain, or discomfort in anyone under 18 with a current or recent viral illness. The one guideline-endorsed exception is Kawasaki disease acute/maintenance-phase therapy — see the Kawasaki Disease chapter. |
| Bismuth subsalicylate | Use in this context: Contraindicated — counsel explicitly, since the name does not suggest "aspirin" to most caregivers | Same Reye syndrome association as ASA when used during a viral illness in this age group | Additive bleeding risk with other antiplatelets/anticoagulants; may cause harmless black stool/tongue discolouration | The single most commonly missed "hidden" salicylate — marketed for upset stomach/diarrhea/nausea, not recognized by most caregivers as aspirin-related, and often reached for specifically during the viral GI illness that is itself a Reye syndrome trigger. |
Safe Antipyretic/Analgesic Alternatives
Preferred, effective substitutes for any fever, pain, or discomfort in a child or teenager under 18, with no Reye syndrome association.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Acetaminophen | Children/teens: Weight-based dosing per the current product monograph, typically every 4-6 hours as needed | Hepatotoxicity with overdose or in significant hepatic impairment | None significant at standard doses | First-line recommendation for this age group; dose cautiously if hepatic involvement is already suspected or confirmed. |
| Ibuprofen | Children over 6 months/teens: Weight-based dosing per the current product monograph, typically every 6-8 hours as needed | GI upset; renal effects with dehydration | Avoid combining with other NSAIDs | Effective alternative or adjunct to acetaminophen; avoid under 6 months of age without consulting a healthcare provider. |
Acute Supportive/ICU Therapy for Confirmed or Presumed Reye Syndrome
No agent here is disease-modifying — all are supportive, targeting a specific complication of the encephalopathy/hepatopathy. Specialist/ICU-directed dosing throughout.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Dextrose (IV) | Dosing: Dextrose-containing IV fluids, titrated to target glucose; monitor serially | Hyperglycemia with over-correction | None clinically significant at standard use | Corrects and maintains euglycemia, targeting roughly 100-120 mg/dL; hypoglycemia is common, especially in younger children. |
| Mannitol | Dosing: Specialist/ICU-directed, guided by ICP monitoring where available | Dehydration, electrolyte disturbance, rebound intracranial pressure elevation with prolonged use | Additive dehydration/electrolyte effects with diuretics | Osmotic therapy for acutely elevated intracranial pressure in Stage 3+ disease; used alongside head-of-bed elevation, normothermia, and sedation. |
| Hypertonic saline | Dosing: Per institutional critical-care protocol | Hypernatremia, fluid overload | Additive effects with other hypertonic/osmotic agents | Alternative osmotic agent to mannitol for elevated intracranial pressure; specialist/ICU-directed. |
| Vitamin K1 | Dosing: Specialist-directed, per current product monograph | Rare injection-site or hypersensitivity reactions | Reverses/limits efficacy of warfarin if co-administered | Corrects prolonged prothrombin time from hepatic synthetic dysfunction; add fresh frozen plasma or cryoprecipitate for active bleeding. |
| Fresh frozen plasma / cryoprecipitate | Dosing: Per institutional transfusion protocol | Transfusion reactions, fluid overload | None clinically significant beyond standard transfusion precautions | For active bleeding or significant coagulopathy, particularly before an invasive procedure such as ICP monitor placement. |
| Sodium benzoate / sodium phenylacetate | Dosing: Specialist/metabolic-team-directed only | GI upset, hypernatremia with repeated dosing | Specialist-directed; typically used under metabolic/toxicology guidance | Ammonia-scavenging therapy considered for severe hyperammonemia; hemodialysis/continuous renal replacement therapy is an option at markedly elevated levels (StatPearls cites a threshold above roughly 500 mcg/dL). |
Symptomatic Adjuncts
Supportive only — never a substitute for recognizing and escalating the red-flag vomiting-plus-altered-mental-status pattern itself.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Ondansetron | Dosing: Weight-based dosing per the current product monograph | Headache, QT prolongation at high doses | Additive QT-prolongation risk with other QT-prolonging drugs | Symptomatic control of persistent vomiting once the diagnosis/differential is being actively worked up in a monitored setting. |
References
- Reye's Syndrome — Health Canada. Health Canada, canada.ca, last modified 2017 May 4
- Guidance Document — Acetylsalicylic Acid Labelling Standard — Health Canada, Therapeutic Products Directorate. Health Canada guidance document, adopted 2013 Aug 21, effective 2013 Oct 17
- Reye's Syndrome in the United States from 1981 through 1997 — New England Journal of Medicine (Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB). N Engl J Med 1999;340(18):1377-1382
- Reye Syndrome — StatPearls, NCBI Bookshelf (Chapman J, Arnold JK). StatPearls Publishing, last updated 2023 Jul 4 (Bookshelf ID NBK526101)
- Trends in the incidence of Reye's syndrome and the use of aspirin — Archives of Disease in Childhood (Porter JD, Robinson PH, Glasgow JF, Banks JH, Hall SM). Arch Dis Child 1990;65(8):826-829
- Reye syndrome — HealthLinkBC (British Columbia Ministry of Health / Provincial Health Services Authority). HealthLinkBC File, last reviewed 2023 Oct 13
- Reye Syndrome — Merck Manual Professional Edition. Merck Manual Professional Edition, Pediatrics section
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.